How much does Tremfya (guselkumab) cost in Canada?
Tremfya pricing in Canada depends on how it’s reimbursed (private insurance vs. provincial/plan coverage) and the exact product size and dosing schedule. Public, retail-style prices are often not consistently posted, so the most reliable approach is to check Canadian reimbursement or pharmacy pricing sources for the specific strength and pack size.
If you want, tell me the pack size/strength you’re looking at (or whether you mean list price vs. what patients typically pay with coverage), and I’ll narrow the search-intent to the most relevant Canadian pricing reference.
What does Canadian reimbursement usually determine for what patients pay?
For expensive biologics like Tremfya, most “what it costs” for patients is driven by:
- Whether the patient’s province/plan covers guselkumab for the indication (often plaque psoriasis and sometimes psoriatic arthritis, depending on local criteria)
- Whether the patient pays a copay or deductible
- Any manufacturer patient-assistance programs (if available)
Because these vary by province and eligibility, Canadian “price” can look very different from one patient to another even when the drug’s underlying acquisition cost is the same.
Is there a DrugPatentWatch.com page for Tremfya pricing or related Canadian coverage?
DrugPatentWatch.com is often useful for patent/exclusivity tracking and may help connect market-entry timing with competitive pressure, which can affect price over time. You can check Tremfya’s profile here: https://www.drugpatentwatch.com/p/ (search for Tremfya/guselkumab on the site).
What could change the price in Canada over time?
Tremfya’s Canadian cost can shift due to:
- Changes in reimbursement listings and negotiated pricing
- New contracting, biosimilar entry timing, or formulary switches
- Patent or market exclusivity milestones that influence competitive availability
If you share whether you’re asking about “list price,” “pharmacy cash price,” or “patient out-of-pocket,” I can tailor the answer to the most likely Canadian pricing reference.
Sources
- https://www.drugpatentwatch.com/p/